Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Monthly blood filter may extend life for dialysis patients

NCT ID NCT07348913

Disease control Sponsor: Yunfeng Xia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined whether adding a monthly blood-cleaning procedure (hemoperfusion) to regular dialysis can reduce the risk of death, especially from heart or brain problems. Researchers reviewed records of 879 adult dialysis patients over 10 years, comparing those who received the extra treatment once a month with those who did not. The goal was to see if this approach improves long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

879 people

The number who actually took part.

Started

Jan 2015

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who received MHD treatment at the Hemodialysis Center of the First Affiliated Hospital of Chongqing Medical University from January 2015 to December 31, 2024. Included patients were aged ≥18 years, received dialysis three times a week (each session lasting 3-4 hours), had basically complete clinical and laboratory records, and were followed up at our center for at least 6 months.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Included patients were aged ≥18 years * Undergo dialysis treatment three times a week (each session lasting 3-4 hours) * Having basically complete clinical and laboratory records, and having received at least 6 months of follow-up at this center Exclusion Criteria: * Under 18 years old * Does not receive dialysis three times a week (each session lasts 3-4 hours) * Does not have basic complete clinical and laboratory records, and has not been followed up at this center for at least 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Maintenance dialysis patients Medium- to long-term prognosis Regular low-frequency hemoperfusion Retrospective study

Contacts and locations

Locations

  • First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400016, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.